I am a retired P.M.D. forensic analyst and I share my investment insights in economics. I am a high-powered mind with a forensic edge — part Wall Street watchdog, part biotech sleuth, part AI futurist. I chase truth like a bloodhound through economic data, FDA filings, and GPU benchmarks. I’ve ...
moreI am a retired P.M.D. forensic analyst and I share my investment insights in economics. I am a high-powered mind with a forensic edge — part Wall Street watchdog, part biotech sleuth, part AI futurist. I chase truth like a bloodhound through economic data, FDA filings, and GPU benchmarks. I’ve built investment theorems sharper than any hedge fund model, with a doctrine of austerity over emotion and a nest egg strategy forged in market fire.
My questions don’t just scratch the surface — they drill deep into regulatory pipelines, neural networks, and America’s spine (sometimes literally, given your dive into spinal surgery!). I mix patriotism with pragmatism, always looking for the companies, policies, and technologies that align with America’s future — while keeping a side-eye on the Deep State’s playbook.
I demand precision, context, and performance — in medicine, in machines, and in markets. I am part analyst, part philosopher, part watchdog with a mission.
I’ve been asked this — “when did you first realize your talent for spotting patterns where others just see noise?” I am a seasoned medical expert with a passion for biopharma and trained as a forensic analyst, with a background in economics. I specialize in developing and applying innovative theorems to dissect the intersection of austerity measures, Coaseian oppression, and investment strategies. My work, including theorems on protective nest egg management and critical lifestyle investing rules, is designed to remove emotional biases from decision-making and empower investors to achieve financial resilience using dependent Point & Figure charting along with many different studies and candlestick charting.
With over 30 years of analytical experience, I have honed my expertise in identifying market opportunities and crafting actionable strategies for buy, sell, and hold decisions, including advanced options trading techniques. My analyses are informed by a deep understanding of demographic economics, examining long-term market impacts and their implications for individual investors and societal well-being.
Mission and Writing Philosophy
Through platforms such as TalkMarkets, Bezinga, MorningStar, and Seeking Alpha as partners in my submitted publications, I provide investors with insightful, evidence-based articles that explore critical financial and economic issues. My journey as a writer began during the global financial crisis, addressing systemic financial reform and the challenges of safeguarding investments in a volatile and austerity-driven environment.
A central theme of my work is to challenge conventional thinking—presenting data and theorems that may initially seem far-fetched but ultimately prove grounded in reality. My goal is to educate and provoke thought, encouraging readers to explore new perspectives on investment strategies and economic trends.
Commitment to Readers
I strive to foster interactive discussions within the investment community, inviting both seasoned professionals and newcomers to engage with my ideas. Each article is crafted to stimulate critical thought and raise awareness of the forces shaping economic and market dynamics.
Disclaimer
Legal and Investment Advisory Disclaimer
I am not a registered investment adviser, broker, or research analyst. My commentary and analyses are provided for informational purposes only and are not intended as offers to buy or sell securities. While I base my work on reliable sources and provide my insights in good faith, I urge readers to independently verify all claims and consult with qualified financial advisers before making investment decisions.
Investing carries significant risks, including the potential for substantial losses. Past performance is not indicative of future results, and all investment decisions should be made with a full understanding of the associated risks. Neither I nor Seeking Alpha accept any liability for losses incurred from the use of this information.
less
Latest Comments
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
How Science Meets A.I.
KEEPING YOUR EYE ON THE TRUTH CAN BE A DIFFERENCE BETWEEN BEING IN $CAPR INSTEAD OF OUT OF A LONG POSITION.
President-elect Donald Trump has nominated Dr. Marty Makary, a surgeon and public policy researcher at Johns Hopkins University, to lead the U.S. Food and Drug Administration (FDA). Dr. Makary is known for his criticism of certain public health measures during the COVID-19 pandemic and has advocated for reducing bureaucratic obstacles within federal health agencies.
Dr. Makary’s approach to the FDA’s drug approval process emphasizes streamlining procedures to expedite the availability of treatments for serious conditions, such as Duchenne Muscular Dystrophy (DMD). He has expressed concerns about the agency’s “cozy relationship” with drug manufacturers and has criticized specific FDA decisions, including the approval of certain COVID-19 vaccines and Alzheimer’s treatments.
The FDA has recently approved several treatments for DMD, including:
• Elevidys (delandistrogene moxeparvovec): A gene therapy approved in June 2023 for pediatric patients aged 4 through 5 years with a confirmed mutation in the DMD gene.
• Duvyzat (givinostat): An oral medication approved in March 2024 for the treatment of DMD in patients six years and older, representing the first nonsteroidal drug approved for all genetic variants of DMD.
Dr. Makary’s potential leadership could influence the FDA’s approach to approving such treatments. While his intent to reduce bureaucratic delays may accelerate the availability of new therapies, his critical stance on certain FDA decisions suggests he may implement more stringent evaluation processes to ensure drug efficacy and safety.
In summary, Dr. Makary’s nomination indicates a potential shift in the FDA’s drug approval process, aiming to balance expedited access to treatments for diseases like DMD with rigorous scientific evaluation to maintain public trust and safety.
The Dream Team Disruptors - Einstein's In Biopharma 2020-2021
Keeping an eye out on Mesoblast MESO having a halt/pause in trading 12/16/2020 pre-opening. We see they are nearing a probable M&A event significantly increasing current share price well into $41-$78 dollars a share since they announced Phase III trial for CHF, but the actual positive results in saving lives from CV.
We are also upbeat with Arca Biopharma ABIO as can relate to current positive announcement from:
Dr. Wolfram Ruf, Scientific Director of the Center for Thrombosis and Hemostasis at the Johannes Gutenberg University Medical Center Mainz, Germany, and Professor at Scripps Research, La Jolla, CA, commented, “The clinical course of some patients with COVID-19 is complicated by a virus-triggered coagulopathy that includes thrombotic events and inflammatory processes, thought to be mediated in part by tissue factor production. Because rNAPc2 is a potent tissue factor inhibitor, it has anticoagulant with anti-inflammatory and antiviral properties. With its properties in modulating the tissue factor pathway, rNAPc2 has the potential to be a uniquely beneficial therapy for patients hospitalized with COVID-19, and potentially other RNA virus associated diseases as well.”
We also suggest not to downplay Capricor CAPR with their VLP and mRNA SGV's true worldwide potentials being extremely robust with extensive spike-protein coverages without the actual side effects as being documented out of Pfizer's, Moderna's, and other FGV's currently having FDA EUA approval.
The other wakeup call is being sent with CytoDyn CYDY with their quite successful COVID-19 Long-Hauler trial. China's Plague sent the world is not going away anytime soon, even with the EUA FGV's being deployed.
We don't need to keep bringing major Lockdowns as being enacted by countries and states around the world. The answer in why no lockdowns needed come with the major Severe COVID-19 Infected patient treatments being provided by REGN, CYDY, ELY, ABIO, CAPR, AXDX, MESO, and SPPI.
The Dream Team Disruptors - Einstein's In Biopharma 2020-2021
Thank you William for the kind thoughts.
Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
Thanks for the complement!
Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
What will bring all back to work! Joe Biden is clueless... Keeping the eyes on the prize! POTUS Capricor, CAPR yesterday, beat on all numbers and has brought a VLP Vaccine into the long-term solutions FDA TRIALS CAP-1002. talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon PT $14 - $24 3-12 month outlook.